Tag:
Prevnar-13
Latest Headlines
Latest Headlines
FDA delays decision on Pfizer's Prevnar 13
The FDA will take 90 more days to review Pfizer's request that Prevnar 13 be approved for adults 50 and over. Pfizer has submitted additional data gathered from two studies of the vaccine used in
FDA extends Prevnar review on additional data
The FDA has put off its decision on expanding the use of Pfizer's Prevnar 13 vaccine to adults 50 and older. A decision is now expected 90 days later in January 2012. Pfizer release | Report
Prevnar-13 effective in adults over 50 in Ph3 trial
Pfizer has released positive results for its pneumococcal vaccine, Prevnar-13. The vaccine was more effective in adults over age 50 than the current vaccine recommended for adults over 65. And those
Pfizer's next top seller aces trials for new use
Pfizer has gotten some good news on Prevnar 13, its new-generation pneumococcal vaccine. It proved at least as effective in adults as Merck's Pneumovax, according to new study data. Acquired in its
Interview: Pfizer vaccine unit eyes adults, infectious disease
When Pfizer was searching for a major acquisition in 2009, it saw a lot it liked in Wyeth--including an established vaccine group that could jump-start its own efforts in that area. Pfizer had a
Kenya begins GSK pneumococcal vax distribution
As part of a nationwide project and a worldwide child immunization effort, Kenya started distributing a pneumococcal vaccine to the public Feb. 14. The vaccine, made by GlaxoSmithKline, will be given
Prevnar 13: Pfizer's next Lipitor?
Pfizer got double good news Wednesday after the FDA approved Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the company's 13-valent pneumococcal conjugate vaccine.
Pfizer seeks $1.5B adult market for Prevnar 13
Pfizer has high hopes for Prevnar-13, the vaccine it acquired in its buyout of Wyeth. An FDA panel has already voted in favor of the updated vaccine, and the company is awaiting final approval of the
FDA panel says yes to updated Prevnar
The new Pfizer-Wyeth got good news Wednesday after an FDA panel determined that the company's updated version of childhood vaccine Prevnar is safe and effective. In a 10-1 vote, the FDA's Vaccines
Wyeth seeks FDA approval to market Prevnar 13
Wyeth has filed for FDA approval of its improved version of Prevnar for infants and plans to seek expanded authority next year to use it to protect adults. Prevnar 13 guards against the same seven
